203 related articles for article (PubMed ID: 22703232)
1. Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer.
Moi LL; Flågeng MH; Gjerde J; Madsen A; Røst TH; Gudbrandsen OA; Lien EA; Mellgren G
BMC Cancer; 2012 Jun; 12():247. PubMed ID: 22703232
[TBL] [Abstract][Full Text] [Related]
2. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
Osborne CK; Bardou V; Hopp TA; Chamness GC; Hilsenbeck SG; Fuqua SA; Wong J; Allred DC; Clark GM; Schiff R
J Natl Cancer Inst; 2003 Mar; 95(5):353-61. PubMed ID: 12618500
[TBL] [Abstract][Full Text] [Related]
3. Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue.
Haugan Moi LL; Hauglid Flågeng M; Gandini S; Guerrieri-Gonzaga A; Bonanni B; Lazzeroni M; Gjerde J; Lien EA; DeCensi A; Mellgren G
Clin Cancer Res; 2010 Apr; 16(7):2176-86. PubMed ID: 20332317
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.
Lindberg K; Helguero LA; Omoto Y; Gustafsson JÅ; Haldosén LA
Breast Cancer Res; 2011 Apr; 13(2):R43. PubMed ID: 21492444
[TBL] [Abstract][Full Text] [Related]
6. Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer.
Myers E; Hill AD; Kelly G; McDermott EW; O'Higgins NJ; Buggy Y; Young LS
Clin Cancer Res; 2005 Mar; 11(6):2111-22. PubMed ID: 15788656
[TBL] [Abstract][Full Text] [Related]
7. mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen.
Revillion F; Pawlowski V; Lhotellier V; Louchez MM; Peyrat JP
Anticancer Res; 2003; 23(2B):1455-60. PubMed ID: 12820409
[TBL] [Abstract][Full Text] [Related]
8. Lifetime Genistein Intake Increases the Response of Mammary Tumors to Tamoxifen in Rats.
Zhang X; Cook KL; Warri A; Cruz IM; Rosim M; Riskin J; Helferich W; Doerge D; Clarke R; Hilakivi-Clarke L
Clin Cancer Res; 2017 Feb; 23(3):814-824. PubMed ID: 28148690
[TBL] [Abstract][Full Text] [Related]
9. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2.
Jhabvala-Romero F; Evans A; Guo S; Denton M; Clinton GM
Oncogene; 2003 Nov; 22(50):8178-86. PubMed ID: 14603258
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
11. The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity.
Shah YM; Rowan BG
Mol Endocrinol; 2005 Mar; 19(3):732-48. PubMed ID: 15528270
[TBL] [Abstract][Full Text] [Related]
12. Effects of In Utero Exposure to Ethinyl Estradiol on Tamoxifen Resistance and Breast Cancer Recurrence in a Preclinical Model.
Hilakivi-Clarke L; Wärri A; Bouker KB; Zhang X; Cook KL; Jin L; Zwart A; Nguyen N; Hu R; Cruz MI; de Assis S; Wang X; Xuan J; Wang Y; Wehrenberg B; Clarke R
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27609189
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
[TBL] [Abstract][Full Text] [Related]
14. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
Arpino G; Green SJ; Allred DC; Lew D; Martino S; Osborne CK; Elledge RM
Clin Cancer Res; 2004 Sep; 10(17):5670-6. PubMed ID: 15355892
[TBL] [Abstract][Full Text] [Related]
15. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
16. Distinctive functions of p160 steroid receptor coactivators in proliferation of an estrogen-independent, tamoxifen-resistant breast cancer cell line.
Karmakar S; Foster EA; Blackmore JK; Smith CL
Endocr Relat Cancer; 2011 Feb; 18(1):113-27. PubMed ID: 21059860
[TBL] [Abstract][Full Text] [Related]
17. Schizophyllan inhibits the development of mammary and hepatic carcinomas induced by 7,12 dimethylbenz(α)anthracene and decreases cell proliferation: comparison with tamoxifen.
Mansour A; Daba A; Baddour N; El-Saadani M; Aleem E
J Cancer Res Clin Oncol; 2012 Sep; 138(9):1579-96. PubMed ID: 22552717
[TBL] [Abstract][Full Text] [Related]
18. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.
Gutierrez MC; Detre S; Johnston S; Mohsin SK; Shou J; Allred DC; Schiff R; Osborne CK; Dowsett M
J Clin Oncol; 2005 Apr; 23(11):2469-76. PubMed ID: 15753463
[TBL] [Abstract][Full Text] [Related]
19. In vivo inhibition of the estrogen sulfatase enzyme and growth of DMBA-induced mammary tumors by melatonin.
González A; Alvarez-García V; Martínez-Campa C; Mediavilla MD; Alonso-González C; Sánchez-Barceló EJ; Cos S
Curr Cancer Drug Targets; 2010 May; 10(3):279-86. PubMed ID: 20370689
[TBL] [Abstract][Full Text] [Related]
20. Effects of Jaeumkanghwa-tang on tamoxifen responsiveness in preclinical ER+ breast cancer model.
De Oliveira Andrade F; Yu W; Zhang X; Carney E; Hu R; Clarke R; FitzGerald K; Hilakivi-Clarke L
Endocr Relat Cancer; 2019 Mar; 26(3):339-353. PubMed ID: 30640711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
